Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy

被引:37
|
作者
Cigler, Tessa [1 ]
Isseroff, Devora [1 ]
Fiederlein, Barbara [1 ]
Schneider, Sarah [1 ]
Chuang, Ellen [1 ]
Vandat, Linda [1 ]
Moore, Anne [1 ]
机构
[1] Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY USA
关键词
Alopecia; Breast cancer; Chemotherapy; Cold cap; Cryotherapy; INDUCED HAIR LOSS; SYSTEM;
D O I
10.1016/j.clbc.2015.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Scalp cryotherapy may prevent chemotherapy associated alopecia (CIA). Degree of hair loss in 20 women electing to use scalp cooling during TC chemotherapy for breast cancer was assessed. After completion of chemotherapy only 2 (10%) reported the need to wear a wig or head covering. Scalp cooling appears to be effective in preventing CIA with a common chemotherapy regimen. Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy agents. The TC (docetaxel [Taxotere] and cyclophosphamide) chemotherapy regimen is typically associated with complete alopecia. Scalp cooling with cold caps has been reported to minimize or prevent CIA. We conducted a prospective study to assess efficacy of scalp cooling in preventing CIA among women receiving adjuvant TC chemotherapy for breast cancer. Methods: Women at the Weill Cornell Breast Center who independently elected to use scalp cooling with cold caps during adjuvant TC chemotherapy were asked to participate. Degree of hair loss was assessed by a single practitioner using Dean's alopecia'scale (grade 1/excellent [< 25% hair loss], grade 2/good [25%-50% hair loss], grade 3/moderate [50%-75% hair loss], grade 4/poor [> 75% hair loss]), by digital photographs, and by patient self-report of hair thinning or the need to wear a wig/head covering, or both. Assessments were made before each chemotherapy treatment and at follow-up visits between 3 weeks and 3 months after completion of chemotherapy. Results: Of 20 evaluable patients, 10% reported a need to wear a wig/head covering at the follow-up visit. Dean's alopecia score was excellent for 65% of patients, good for 25% of patients, and moderate or poor for 10% of patients. The majority of patients reported hair thinning after every chemotherapy cycle. No patient discontinued therapy because of an intolerance to cold caps. Conclusion: Scalp cooling with cold caps appears to be effective in preventing CIA among the majority of women undergoing treatment with TC chemotherapy.
引用
收藏
页码:332 / 334
页数:3
相关论文
共 50 条
  • [41] Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy
    Tsuji, Daiki
    Matsumoto, Megumi
    Kawasaki, Yohei
    Kim, Yong-I. L.
    Yamamoto, Keisuke
    Nakamichi, Hidenori
    Sahara, Yuri
    Makuta, Ryo
    Yokoi, Mari
    Miyagi, Takehiro
    Itoh, Kunihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 73 - 83
  • [42] Chemotherapy-induced irreversible alopecia in early breast cancer patients
    Gun Min Kim
    Sanghwa Kim
    Hyung Seok Park
    Jee Ye Kim
    Sanggen Nam
    Seho Park
    Seung Il Kim
    DoYoung Kim
    Joohyuk Sohn
    Breast Cancer Research and Treatment, 2017, 163 : 527 - 533
  • [43] Chemotherapy-induced irreversible alopecia in early breast cancer patients
    Kim, Gun Min
    Kim, Sanghwa
    Park, Hyung Seok
    Kim, Jee Ye
    Nam, Sanggen
    Park, Seho
    Kim, Seung Il
    Kim, DoYoung
    Sohn, Joohyuk
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 527 - 533
  • [44] Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy
    Manon M. C. Komen
    Corina J. G. van den Hurk
    Johan W. R. Nortier
    Tjeerd van der Ploeg
    P. Nieboer
    Jacobus J. M. van der Hoeven
    Carolien H. Smorenburg
    Supportive Care in Cancer, 2019, 27 : 1919 - 1925
  • [45] Redefining the "crown": Approaching chemotherapy-induced alopecia among Black patients with breast cancer
    Pleasant, Versha A.
    Purkiss, Ava S.
    Merjaver, Sofia D.
    CANCER, 2023, 129 (11) : 1629 - 1633
  • [46] Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
    Kluger, N.
    Jacot, W.
    Frouin, E.
    Rigau, V.
    Poujol, S.
    Dereure, O.
    Guillot, B.
    Romieu, G.
    Bessis, D.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2879 - 2884
  • [47] Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
    Martin, M.
    de la Torre-Montero, J. C.
    Lopez-Tarruella, S.
    Pinilla, K.
    Casado, A.
    Fernandez, S.
    Jerez, Y.
    Puente, J.
    Palomero, I.
    Gonzalez del Val, R.
    del Monte-Millan, M.
    Massarrah, T.
    Vila, C.
    Garcia-Paredes, B.
    Garcia-Saenz, J. A.
    Lluch, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 627 - 634
  • [48] Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients
    Takabatake, Daisuke
    Taira, Naruto
    Hara, Fumikata
    Sien, Tadahiko
    Kiyoto, Sachiko
    Takashima, Seiki
    Aogi, Kenjiro
    Ohsumi, Shozo
    Doihara, Hiroyoshi
    Takashima, Shigemitu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (08) : 478 - 483
  • [49] Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer - clinical evaluation of sensor-controlled scalp cooling
    Friedrichs, Kay
    Carstensen, Martin H.
    SPRINGERPLUS, 2014, 3
  • [50] Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
    Perez, Aleymi M.
    Haberland, Nicole I.
    Miteva, Mariya
    Wikramanayake, Tongyu C.
    CURRENT ONCOLOGY, 2024, 31 (09) : 5709 - 5721